Breast Cancer Update

Featuring perspectives from Ms Kelly Fischer, Dr Marissa Marti-Smith, Dr Rita Nanda and Dr Ruth M O'Regan, moderated by Dr Nanda, including the following topics:
Introduction (00:00)
Advent of CDK4/6 Inhibitors in HR-Positive Breast Cancer (BC) (1:24)
Risk Assessment for Patients with HR-Positive, HER2-Negative Localized BC (2:52)
Adjuvant CDK4/6 Inhibitor Therapy (17:14)
Practical Considerations with CDK4/6 Inhibitors (29:57)
Monitoring and Management of Cytopenias (42:02)
CDK4/6 Inhibitors in HR-Positive Metastatic BC (49:32)
Management of Gastrointestinal Adverse Events (1:03:47)
CDK4/6 Inhibitors in Unique Populations (1:10:41)
Rarer CDK4/6 Inhibitor-Associated Toxicities (1:19:48)

CME information and select publications

Featuring perspectives from Dr Sara A Hurvitz, Dr Erica Mayer, Dr Joyce O’Shaughnessy, Dr Sara M Tolaney and Dr Nicholas Turner, moderated by Dr Tolaney, including the following topics:
Introduction (0:00)
Current and Future Roles of Agents Targeting the PI3K/AKT/mTOR Pathway and Oral Selective Estrogen Receptor Degraders (SERDs) in First-Line Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Turner (2:35)
Role of Oral SERD Monotherapy in the Treatment of Progressive HR-Positive, HER2-Negative mBC — Dr O’Shaughnessy (25:23)
Potential Use of Oral SERD-Containing Combination Regimens in Managing Progressive HR-Positive, HER2-Negative mBC — Dr Mayer (46:29)
Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive, HER2-Negative mBC — Dr Hurvitz (1:07:06)
Potential Use of Oral SERDs for HR-Positive, HER2-Negative Localized Breast Cancer — Dr Tolaney (1:38:17)

CME information and select publications

Featuring an interview with Prof Dr Sibylle Loibl, including the following topics:
Perspectives on overall survival gains achieved over the years for patients with metastatic breast cancer (mBC) (0:00)
Previous treatment and patient outcomes in the DESTINY-Breast09 trial of trastuzumab deruxtecan (T-DXd) with or without pertuzumab (5:35)
Role of endocrine therapy in the treatment of hormone receptor-positive, HER2-positive mBC (8:01)
Targeting the PI3K signaling pathway in HER2-positive mBC (11:08)
Contraindications for T-DXd; T-DXd-associated gastrointestinal toxicities and interstitial lung disease (13:53)
Optimal duration of and therapeutic partner for T-DXd as first-line maintenance therapy for patients with HER2-positive mBC (20:44)
Case: A woman in her early 40s with metastatic relapse of HER2-positive breast cancer 2 years after completing neoadjuvant and adjuvant therapy (26:54)
Role of exercise and weight control in the management of breast cancer; effect of pregnancy on the breast tumor immune environment (40:03)

CME information and select publications

Featuring perspectives from Dr Harold J Burstein and Dr Joyce O’Shaughnessy, including the following topics:
Introduction: ODAC — April 30, 2026 (00:00)
Adjuvant CDK4/6 Inhibitors (13:03)
Adjuvant Oral Selective Estrogen Receptor Degraders (21:53)
Premenopausal Patients (30:52)
Duration of Adjuvant Endocrine Treatment (38:44)
Genomic Predictors of Chemotherapy Benefit (47:19)
Neoadjuvant Treatment (55:13)

CME information and select publications

Featuring perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics:
Introduction (0:00)
Overview of Antibody-Drug Conjugates (ADCs) (2:07)
Current and Future Role of HER2-Targeted ADCs for Breast Cancer (6:23)
Currently Available ADCs for Gynecologic Cancer Management (26:37)
Currently Available ADCs for Lung Cancer Management (44:07)
Current and Future Role of TROP2-Targeted ADCs for Metastatic Breast Cancer (56:55)
Other ADCs That May Soon Reach the Clinic for Advanced Gynecologic Cancers (1:15:07)
Promising Investigational Strategies Employing ADCs for Lung Cancer (1:25:01)

NCPD information and select publications